Active	Status	Sponsor type	Region	Phase	Filter
3 Active 1 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Lehman, Heather
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy	Active, not recruiting	3	165	Europe, Canada, Japan, US, RoW	Ligelizumab 120 mg, Ligelizumab 240 mg	Novartis Pharmaceuticals	Food Allergy	02/25	02/25
NCT03878069: Registry Study of Revcovi Treatment in Patients With ADA-SCID	Completed	N/A	32	US	elapegademase-lvlr, Revcovi	Chiesi Farmaceutici S.p.A.	Adenosine Deaminase Severe Combined Immunodeficiency	01/23	01/23
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC	Recruiting	N/A	15000	Europe, Canada, US		Target PharmaSolutions, Inc.	Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria	12/50	12/50